Prometheus Laboratories Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$22.5M
Doctors Paid
4,202
Transactions
12,534
2018 Total
$11.7M
Payment Breakdown by Category
Research$21.1M (93.9%)
Consulting$842,506 (3.7%)
Food & Beverage$184,197 (0.8%)
Travel$42,181 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21.1M | 2,057 | 93.9% |
| Consulting Fee | $842,506 | 154 | 3.7% |
| Food and Beverage | $184,197 | 9,869 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $162,796 | 127 | 0.7% |
| Grant | $82,500 | 19 | 0.4% |
| Honoraria | $60,750 | 31 | 0.3% |
| Travel and Lodging | $42,181 | 103 | 0.2% |
| Education | $2,443 | 174 | 0.0% |
Payments by Type
Research
$21.1M
2,057 transactions
General
$1.4M
10,477 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease | $2.2M | 0 | 14 |
| A Phase I Study of Individual Adult and Pediatric Patient Dose-Escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease | $2.0M | 0 | 15 |
| A Phase I Trial of Regulatory T-Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease | $1.9M | 0 | 16 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients with Metastatic Uveal Melanoma | $1.6M | 0 | 5 |
| Procurement of Blood Samples from Subjects with Diagnosed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) for Use in the Development of a Liver Fibrosis Test | $1.4M | 0 | 369 |
| COL16IBD01 - Precision IFX Using a pharmacokinetic Dashboard on optimize and individualize infliximab dosage for pediatric | $991,250 | 0 | 813 |
| MTA16HEP01 - Prometheus NAFLD NASH Diagnostics Collaboration | $892,960 | 0 | 1 |
| Low Dose IL-2 for Treatment of Active Ulcerative Colitis | $669,437 | 0 | 8 |
| COL16HEP01 - Retrospective prospective analysis of biomarkers of NASH NAFLD related disease activity | $660,000 | 0 | 3 |
| 10PLK13 - PROCLAIM Registry | $586,655 | 0 | 101 |
| Lymphodepletion + Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients with Melanoma | $585,587 | 0 | 3 |
| COL17HEP04 - Discovery of microbiome biomarkers in NASH patients | $536,000 | 0 | 2 |
| A Phase I Clinical Trial Combining Nivolumab and Adoptive Cell Therapy for Metastatic Non-small cell lung cancer | $518,202 | 0 | 5 |
| Phase II Trial of Extracorporeal Photophoresis (ECP) plus Low dose IL-2 for the treatment of Steroid Refractory Chronic Graft versus Host Disease (cGVHD) | $440,803 | 0 | 7 |
| A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of a 12-week Add-on Treatment with LT 02 (Delayed Release Phosphatidylcholine Granules) vs. Placebo in Patients with Ulcerative Colitis Refractory to Standard Treatment with Mesalamine Followed by an Optional 24-week Open Label Active Drug Dosing Period | $435,177 | 0 | 186 |
| Low-dose Interleukin-2 and Pembrolizumab Among Patients with Metastatic Melanoma and Renal CEll Carcinoma | $398,878 | 0 | 2 |
| Phase II Trial of Daily LD IL-2 | $390,391 | 0 | 5 |
| Feasibility and Safety Investigation of Adoptive Celll Therapy using TIL in multiple cancers | $390,391 | 0 | 2 |
| A pilot clinical trial combining PD-1 blockade, CD137 agonism and adoptive cell therapy for metastatic melanoma | $385,893 | 0 | 4 |
| Phase I Study of Ultra LD S Q IL-2 | $351,352 | 0 | 8 |
| PHASE Ib TRIAL OF CAR-T HEPATIC ARTERY INFUSIONS DELIVERED WITH THE SUREFIRE INFUSION SYSTEM FOR CEA-EXPRESSING LIVER METASTASES | $309,131 | 0 | 4 |
| A Phase I/II Trial of Interleukin-2 and Pembrolizumab (MK-3475) Combination Therapy for Patients with Advanced Renal Cell Carcinoma | $234,235 | 0 | 1 |
| IIT15PLK02 - Feasibility of RCC Treatment Using 5-in-a-row High-dose IL-2 with Pembrolizumab Priming and Concurrent Dosing | $232,553 | 0 | 4 |
| RES-COL13IBD08 - A Prospective Evaluation of Mucosal Healing in Patients with Inflammatory Bowel Disease | $181,755 | 0 | 2 |
| Pilot study of adoptive cell transfer for the treatment of metastatic cancer that expresses NY-ESO-1 using lymphodepleting conditioning followed by infusion of anti-NY ESO-1 muring TCR-cenen engineeres lymphocytes | $171,323 | 0 | 5 |
| MicroRNA targeting of inhibitory pathways to enhance adoptive cell therapies for human papillomavirus-positive cancers. | $166,340 | 0 | 1 |
| Biomarker-Guided Withdrawal of Immunosuppression in Recipients of Vascularized Composite Tissue Transplants | $140,541 | 0 | 3 |
| 16IBD08 - Procurement of Blood and Stool Samples from Subjects with Diagnosed Inflammatory Bowel Disease for Use in the Development of a Mucosal Healing Test | $138,134 | 0 | 12 |
| IIT16PLK12 - Pilot Study Evaluating Activity of the Combination of anti-PD-1 Antibody with High Dose IL-2 in Metastatic Melanoma | $137,165 | 0 | 7 |
| IIT17PLK06 - A phase II randomized, open label trial of high dose interleukin-2 plus - entinostat for patients with advanced clear cell renal cell carcinoma | $135,005 | 0 | 8 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Dr. Curtis Mcguyer, Md, MD | Anatomic Pathology & Clinical Pathology | San Diego, CA | $299,209 | $0 |
| Dr. Richard Safrin, Md, MD | Anatomic Pathology & Clinical Pathology | San Diego, CA | $299,188 | $0 |
| Dr. Janice Dutcher, M.d, M.D | Specialist | New York, NY | $203,603 | $0 |
| Unknown Provider | — | — | $66,877 | $0 |
| Dr. Shervin Rabizadeh, M.d, M.D | Pediatric Gastroenterology | Los Angeles, CA | $23,112 | $0 |
| Carmelo Cuffari, M.d, M.D | Pediatrics | Baltimore, MD | $23,063 | $0 |
| Dr. Andres Yarur, M.d, M.D | Internal Medicine | Los Angeles, CA | $21,773 | $0 |
| Unknown Provider | — | — | $19,260 | $0 |
| Anish Patel, D.o, D.O | Gastroenterology | Fort Sam Houston, TX | $18,686 | $0 |
| Arthur Kornbluth, Md, MD | Gastroenterology | New York, NY | $14,135 | $0 |
| Eugene Greenberg, Md, MD | Gastroenterology | Urbana, IL | $11,584 | $0 |
| Dr. Scot Lewey, D.o, D.O | Gastroenterology | Longmont, CO | $8,798 | $0 |
| Peyton Berookim, M.d, M.D | Internal Medicine | Beverly Hills, CA | $7,994 | $0 |
| Chandar Singaram, Md, MD | Gastroenterology | Sioux Falls, SD | $7,759 | $0 |
| Shashi Kumar, Md, MD | Gastroenterology | Greensburg, PA | $7,437 | $0 |
| Robert Gish, M.d, M.D | Gastroenterology | Folsom, CA | $6,355 | $0 |
| Ashok Tuteja, Md, MD | Gastroenterology | Salt Lake City, UT | $6,354 | $0 |
| William Sandborn, M.d, M.D | Gastroenterology | San Diego, CA | $5,031 | $0 |
| Jeffrey Tuvlin, Md, MD | Gastroenterology | Louisville, KY | $4,730 | $0 |
| Dr. Ami Naik, M.d, M.D | Gastroenterology | Jackson, TN | $4,465 | $0 |
| Mrs. Tanya Dorff, M.d, M.D | Hematology & Oncology | Duarte, CA | $4,344 | $0 |
| Dr. Gilbert Simoni, M.d., Facg, M.D., FACG | Internal Medicine | Thousand Oaks, CA | $4,135 | $0 |
| Brendan Curti, Md, MD | Medical Oncology | Portland, OR | $4,133 | $0 |
| Dr. Brooks Cash, Md, MD | Gastroenterology | Houston, TX | $3,870 | $0 |
| Milton Gedallovich, M.d, M.D | Gastroenterology | Pembroke Pines, FL | $3,375 | $0 |
About Prometheus Laboratories Inc.
Prometheus Laboratories Inc. has made $22.5M in payments to 4,202 healthcare providers, recorded across 12,534 transactions in the CMS Open Payments database. In 2018, the company paid $11.7M. The top product by payment volume is Proleukin ($14.9M).
Payments were distributed across 75 medical specialties. The top specialty by payment amount is Anatomic Pathology & Clinical Pathology ($598,775 to 18 doctors).
Payment categories include: Food & Beverage ($184,197), Consulting ($842,506), Research ($21.1M), Travel & Lodging ($42,181).
Prometheus Laboratories Inc. is associated with 1 products in the CMS Open Payments database.